NL-OMON47292已完成3 期
A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizures - GWEP1521
GW Research Ltd0 个研究点目标入组 25 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 64（—）
入选标准
- •The most important inclusion criteria are:;• Patient is male or female aged between one and 65 years inclusive.
- •Patient and/or parent(s)/legal representative is willing and able to give informed consent/assent for participation in the study.
- •Well-documented clinical history of epilepsy which is not completely controlled by their current AEDs.
- •Clinical diagnosis of TSC according to criteria agreed by the 2012 International Tuberous Sclerosis Complex Consensus Conference.
- •Taking one or more AEDs at a dose which has been stable for at least four weeks prior to screening.
- •All medications or interventions for epilepsy (including ketogenic diet and any neurostimulation devices for epilepsy) must have been stable for one month prior to screening and the patient is willing to maintain a stable regimen throughout the study.;At the end of the baseline period patients must also meet the following criterion:
- •Completed at least 90% of calls to IVRS during the first 28 days of the baseline period (a minimum of 25 completed calls).
排除标准
- •The most important exclusion criteria are:;• Patient has a history of pseudo-seizures.
- •Patient has undergone general anesthetic in the four weeks prior to screening or randomization.
- •Patient has undergone surgery for epilepsy in the six months prior to screening.
- •Patient is being considered for epilepsy surgery or any procedure involving general anesthesia during the blinded phase of the study.
- •Patient has been taking felbamate for less than one year prior to screening.
- •Patient is taking an oral (mTOR) inhibitor.
- •Patient is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid-based medications, within the three months prior to screening and is unwilling to abstain for the duration for the study.
- •Patient has tumor growth which, in the opinion of the Investigator, could affect the primary endpoint.
- •Patient is female and of child bearing potential, or is male whose partner is of child bearing potential, unless willing to ensure that they or their partner use a highly effective method of birth control (e.g., hormonal contraceptives, intrauterine devices/hormone-releasing systems, bilateral tubal occlusion, vasectomized partner, sexual abstinence) during the study and for three months thereafter.
- •Female patient who is pregnant (positive pregnancy test), lactating or planning pregnancy during the course of the study and for three months thereafter.
- •Patient has received an IMP less than 12 weeks prior to the screening visit.
研究者
相似试验
进行中（未招募）
1 期
A study of UCB0942 in adult patients with highly drug-resistant focal epilepsyEUCTR2014-003330-12-HUCB Biopharma SPR46
进行中（未招募）
1 期
A study of UCB0942 in adult patients with highly drug-resistant focal epilepsyhighly drug-resistant focal epilepsyMedDRA version: 21.1Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852EUCTR2014-003330-12-ITCB Biopharma SR55
招募中
1 期
Safety and efficacy of PC945 in combination with other antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (Opera-T Study)Refractory invasive pulmonary aspergillosis (IPA)MedDRA version: 20.0Level: LLTClassification code 10059259Term: Pulmonary aspergillosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-004554-32-ATPulmocide Ltd123
已完成
不适用
A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of ASP2905 in healthy young males, including an open-label two-period randomized crossover study to compare the pharmacokinetics under fasted and fed conditionsziekte van Alzheimer, schizofrenieAlzheimer's Disease and schizophrenyNL-OMON32022Astellas Pharma68
尚未招募
2 期
A study to evaluate the efficacy of Eclipta prostrata (L.) L. in the treatment of atopic dermatitis in childreAtopic dermatitsC16.320.850RBR-2fqcbrxFaculdade de Medicina de Ribeirão Preto da Universidade de São Paulo - USP